Severe pulmonary arterial hypertension induced by SU5416 and ovalbumin immunization

American Journal of Respiratory Cell and Molecular Biology

Volumn 47, Issue 5, 2012, Pages 679-687

  Mizuno, Shiro ^a,b   Farkas, Laszlo ^a   Al Husseini, Aysar ^a   Farkas, Daniela ^a   Gomez Arroyo, Jose ^a   Kraskauskas, Donatas ^a   Nicolls, Mark R ^c   Cool, Carlyne D ^d   Bogaard, Herman J ^e   Voelkel, Norbert F ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b KANAZAWA MEDICAL UNIVERSITY   (Japan)

^c STANFORD UNIVERSITY   (United States)

^d UNIVERSITY OF COLORADO   (United States)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Hypoxia induced factor 1 ; IL 6; Precursor cell

Indexed keywords

DEXAMETHASONE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 6; OVALBUMIN; SEMAXANIB; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXICITY; DISEASE SEVERITY; DRUG SAFETY; ENZYME INHIBITION; IMMUNIZATION; LUNG ALVEOLUS CELL; LUNG BLOOD VESSEL; MALE; NONHUMAN; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RAT;

ANIMALS; ANTILYMPHOCYTE SERUM; APOPTOSIS; ASPARAGINE; B-LYMPHOCYTES; CASPASE INHIBITORS; CELL PROLIFERATION; DEXAMETHASONE; DISEASE MODELS, ANIMAL; HEMODYNAMICS; HYPERTENSION, PULMONARY; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNIZATION; INDOLES; INTERLEUKIN-6; LUNG; MALE; OVALBUMIN; PROLIFERATING CELL NUCLEAR ANTIGEN; PULMONARY ARTERY; PYRROLES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

RATTUS;

EID: 84868309560     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2012-0077OC     Document Type: Article

References (50)

1. Wagenvoort CA. Plexogenic arteriopathy. Thorax 1994;49:S39-S45.
2. Heath D, Yacoub M. Lung mast cells in plexogenic pulmonary arteriopathy. J Clin Pathol 1991;44:1003-1006.
3. Dorfmuller P, Perros F, Balabanian K, Humbert M. Inflammation in pulmonary arterial hypertension. Eur Respir J 2003;22:358-363.
4. Tuder RM, Voelkel NF. Pulmonary hypertension and inflammation. J Lab Clin Med 1998;132:16-24.
5. Nicolls MR. Autoimmunity and pulmonary hypertension: a perspective. Eur Respir J 2005;26:1110-1118.
6. Price LC, Wort SJ, Perros F, Dorfmüller P, Huertas A, Montani D, Cohen-Kaminsky S, Humbert M. Inflammation in pulmonary arterial hypertension. Chest 2012;141:210-221.
7. Fagan KA, Badesch DB. Pulmonary hypertension associated with connective tissue disease. Prog Cardiovasc Dis 2002;45:225-234.
8. Miyata M, Sakuma F, ItoM,Ohira H, Sato Y, Kasukawa R. Athymic nude rats develop severe pulmonary hypertension following monocrotaline administration. Int Arch Allergy Immunol 2000;121:246-252.
9. Taraseviciene-Stewart L, Nicolls MR, Kraskauskas D, Scerbavicius R, Burns N, Cool C,Wood K, Parr JE, Boackle SA, Voelkel NF. Absence of T cells confers increased pulmonary arterial hypertension and vascular remodeling. Am J Respir Crit Care Med 2007;175:1280-1289.
10. Tamosiuniene R, Tian W, Dhillon G, Wang L, Sung YK, Gera L, Patterson AJ, Agrawal R, Rabinovitch M, Ambler K, et al. Regulatory T cells limit vascular endothelial injury and prevent pulmonary hypertension. Circ Res 2011;109:867-879.
11. Daley E, Emson C, Guignabert C, de Waal Malefyt R, Louten J, Kurup VP, Hogaboam C, Taraseviciene-Stewart L, Voelkel NF, Rabinovitch M, et al. Pulmonary arterial remodeling induced by a Th2 immune response. J Exp Med
12. Witzenrath M, Ahrens B, Kube SM, Hocke AC, Rosseau S, Hamelmann E, Suttorp N, Schütte H. Allergic lung inflammation induces pulmonary vascular hyperresponsiveness. Eur Respir J 2006;28:370-377.
13. Rydell-Törmänen K, Uller L, Erjefält JS. Allergic airway inflammation initiates long-term vascular remodeling of the pulmonary circulation. Int Arch Allergy Immunol 2009;149:251-258.
14. Medoff BD, Okamoto Y, Leyton P, Weng M, Sandall BP, Raher MJ, Kihara S, Bloch KD, Libby P, Luster AD. Adiponectin deficiency increases allergic airway inflammation and pulmonary vascular remodeling. Am J Respir Cell Mol Biol 2009;41:397-406.
15. Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, Mc Mahon G, Waltenberger J, Voelkel NF, Tuder RM. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 2001;15:427-438.
16. Oka M, Homma N, Taraseviciene-Stewart L, Morris KG, Kraskauskas D, Burns N, Voelkel NF, McMurtry IF. Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circ Res 2007;100:923-929.
17. Bogaard HJ, Natarajan R, Mizuno S, Abbate A, Chang PJ, Chau VQ, Hoke NN, Kraskauskas D, Kasper M, Salloum FN, et al. Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats. Am J Respir Crit Care Med 2010;182:652-660.
18. Shimoda LA, Semenza GL. HIF and the lung: role of hypoxia-inducible factors in pulmonary development and disease. Am J Respir Crit Care Med 2011;183:152-156.
19. Soon E, Holmes AM, Treacy CM, Doughty NJ, Southgate L, Machado RD, Trembath RC, Jennings S, Barker L, Nicklin P, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 2010;122:920-927.
20. Selimovic N, Bergh C-H, Andersson B, Sakiniene E, Carlsten H, Rundqvist B. Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension. Eur Respir J 2009;34:662-668.
21. Chaouat A, Savale L, Chouaid C, Tu L, Sztrymf B, Canuet M, Maitre B, Housset B, Brandt C, Le Corvoisier P, et al. Role for interleukin-6 in COPD-related pulmonary hypertension. Chest 2009;136:678-687.
22. Steiner MK, Syrkina OL, Kolliputi N,Mark EJ, Hales CA, Waxman AB. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res 2009;104:236-244.
23. Erzurum S, Rounds SI, Stevens T, Aldred M, Aliotta J, Archer SL, Asosingh K, Balaban R, Bauer N, Bhattacharya J, et al. Strategic plan for lung vascular research: an NHLBI-ORDR workshop report. Am J Respir Crit Care Med 2010;182:1554-1562.
24. Lee KS, Kim SR, Park HS, Park SJ, Min KH, Lee KY, Choe YH, Hong SH, Han HJ, Lee YR, et al. A novel thiol compound, N-acetylcysteine amide, attenuates allergic airway disease by regulating activation of NF-kappaB and hypoxia-inducible factor-1alpha. Exp Mol Med 2007; 39:756-768.
25. Simonneau G, Galiè N, Rubin LJ, Langleben D, Seeger W, Domenighetti G, Gibbs S, Lebrec D, Speich R, Beghetti M, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43:S5-S12.
26. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing Z-C, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54:S43-S54.
27. Butrous G, Ghofrani HA, Grimminger F. Pulmonary vascular disease in the developing world. Circulation 2008;118:1758-1766.
28. White RJ, Meoli DF, Swarthout RF, Kallop DY, Galaria II, Harvey JL, Miller CM, Blaxall BC, Hall CM, Pierce RA, et al. Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2007;293:L583-L590.
29. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, Le Cras TD, Abman S, Hirth PK, Waltenberger J, Voelkel NF. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J Clin Invest 2000;106:1311-1319.
30. Kasahara Y, Tuder RM, Cool CD, Lynch DA, Flores SC, Voelkel NF. Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am J Respir Crit Care Med 2001;163:737-744.
31. Taraseviciene-Stewart L, Gera L, Hirth P, Voelkel NF, Tuder RM, Stewart JM. A bradykinin antagonist and a caspase inhibitor prevent severe pulmonary hypertension in a rat model. Can J Physiol Pharmacol 2002;80:269-274.
32. Lee KS, Kim SR, Park SJ, Min KH, Lee KY, Choe YH, Park SY, Chai OH, Zhang X, Song CH, et al. Mast cells can mediate vascular permeability through regulation of the PI3K-HIF-1αlpha-VEGF axis. Am J Respir Crit Care Med 2008;178:787-797.
33. Crosby A, Jones FM, SouthwoodM, Stewart S, Schermuly R, Butrous G, Dunne DW, Morrell NW. Pulmonary vascular remodeling correlates with lung eggs and cytokines in murine schistosomiasis. Am J Respir Crit Care Med 2010;181:279-288.
34. Lee CG, Link H, Baluk P, Homer RJ, Chapoval S, Bhandari V, Kang MJ, Cohn L, Kim YK, McDonald DM, et al. Vascular endothelial growth factor (VEGF) induces remodeling and enhances Th2-mediated sensitization and inflammation in the lung. Nat Med 2004; 10:1095-1103.
35. Huang Y, Chen X, Dikov MM, Novitskiy SV, Mosse CA, Yang L, Carbone DP. Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. Blood 2007;110:624-631.
36. Li B, Lalani AS, Harding TC, Luan B, Koprivnikar K, Huan Tu G, Prell R, VanRoey MJ, Simmons AD, Jooss K. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin Cancer Res 2006;12:6808-6816.
37. Watanabe H, Mamelak AJ, Wang B, Howell BG, Freed I, Esche C, Nakayama M, Nagasaki G, Hicklin DJ, Kerbel RS, et al. Antivascular endothelial growth factor receptor-2 (Flk-1/KDR) antibody suppresses contact hypersensitivity. Exp Dermatol 2004;13: 671-681.
38. Ray A, LaForge KS, Sehgal PB. On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: enhancer, TATA box, and RNA start site (Inr motif) occlusion. Mol Cell Biol 1990;10:5736-5746.
39. Lesprit P, Godeau B, Authier FJ, Soubrier M, Zuber M, Larroche C, Viard JP, Wechsler B, Gherardi R. Pulmonary hypertension in POEMS syndrome: a new feature mediated by cytokines. Am J Respir Crit Care Med 1998;157:907-911.
40. Allam JS, Kennedy CC, Aksamit TR, Dispenzieri A. Pulmonary manifestations in patients with POEMS syndrome: a retrospective review of 137 patients. Chest 2008;133:969-974.
41. Rached S, Athanazio RA, Dias SA, Jardim C, Souza R. Systemic corticosteroids as first-line treatment in pulmonary hypertension associated with POEMS syndrome. J Bras Pneumol 2009;35:804-808.
42. Miyata M, Ito M, Sasajima T, Ohira H, Kasukawa R. Effect of a serotonin receptor antagonist on interleukin-6-induced pulmonary hypertension in rats. Chest 2001;119:554-561.
43. Nilsson CL, Dillon R, Devakumar A, Shi SDH, Greig M, Rogers JC, Krastins B, Rosenblatt M, Kilmer G, Major M, et al. Quantitative phosphoproteomic analysis of the STAT3/IL-6/HIF1a signaling network: an initial study in GSC11 glioblastoma stem cells. J Proteome Res 2010;9:430-443.
44. Lee SH, Lee YJ, Han HJ. Effect of arachidonic acid on hypoxia-induced IL-6 production in mouse ES cells: involvement of MAPKs, NF-kB, and HIF-1α. J Cell Physiol 2010;222:574-585.
45. Bruning U, Fitzpatrick SF, Frank T, Birtwistle M, Taylor CT, Cheong A. NF-kB and HIF display synergistic behaviour during hypoxic inflammation. Cell Mol Life Sci 2012;69:1319-1329.
46. Hristov M, Weber C. Endothelial progenitor cells in vascular repair and remodeling. Pharmacol Res 2008;58:148-151.
47. Majka S, Alvarez DF. Neovascular capacity of endothelial progenitor cells in the adult pulmonary circulation. Am J Physiol Lung Cell Mol Physiol 2009;296:L868-L869.
48. Diller GP, Thum T, Wilkins MR, Wharton J. Endothelial progenitor cells in pulmonary arterial hypertension. Trends Cardiovasc Med 2010;20:22-29.
49. Urbich C, Aicher A, Heeschen C, Dernbach E, Hofmann WK, Zeiher AM, Dimmeler S. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol 2005;39:733-742.
50. Jun JB, Kuechle M, Harlan JM, Elkon KB. Fibroblast and endothelial apoptosis in systemic sclerosis. Curr Opin Rheumatol 2003;15:756-760.